About Citius Pharmaceuticals, Inc.
https://www.citiuspharma.comCitius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy.
CEO
Leonard L. Mazur
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2017-06-09 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:1.81M
Value:$1.55M
VANGUARD GROUP INC
Shares:166.39K
Value:$142.51K
ARGENT WEALTH MANAGEMENT LLC
Shares:164.44K
Value:$140.85K
Summary
Showing Top 3 of 45
About Citius Pharmaceuticals, Inc.
https://www.citiuspharma.comCitius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $8.75M ▼ | $-8.79M ▲ | 0% | $-0.8 ▲ | $-8.73M ▲ |
| Q2-2025 | $0 | $11.26M ▲ | $-10.92M ▼ | 0% | $-1.27 ▲ | $-11.19M ▼ |
| Q1-2025 | $0 ▼ | $10.04M ▼ | $-9.77M ▲ | 0% ▲ | $-1.3 ▲ | $-9.98M ▲ |
| Q4-2024 | $155.93K ▲ | $11.05M ▲ | $-10.79M ▼ | -6.92K% ▼ | $-1.59 ▼ | $-11M ▼ |
| Q3-2024 | $0 | $10.63M | $-10.57M | 0% | $-1.57 | $-10.58M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $6.09M ▲ | $127.68M ▲ | $60.12M ▲ | $65.06M ▲ |
| Q2-2025 | $26.41K ▼ | $121.48M ▲ | $57.91M ▲ | $60.66M ▼ |
| Q1-2025 | $1.1M ▼ | $120.7M ▲ | $51.78M ▲ | $65.41M ▼ |
| Q4-2024 | $3.25M ▼ | $116.65M ▲ | $42.55M ▲ | $70.08M ▼ |
| Q3-2024 | $17.91M | $97.09M | $10.81M | $85.68M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-9.2M ▲ | $-5.41M ▼ | $0 | $11.47M ▲ | $6.06M ▲ | $-5.41M ▼ |
| Q2-2025 | $-11.51M ▼ | $-4.54M ▲ | $0 | $3.47M ▲ | $-1.07M ▲ | $-4.54M ▲ |
| Q1-2025 | $-10.28M ▲ | $-4.73M ▲ | $0 ▲ | $2.57M ▲ | $-2.15M ▲ | $-4.73M ▲ |
| Q4-2024 | $-11.08M ▼ | $-5.91M ▲ | $-5M ▼ | $-3.75M ▼ | $-14.66M ▼ | $-5.91M ▲ |
| Q3-2024 | $-10.57M | $-8.37M | $0 | $13.72M | $5.35M | $-8.37M |
CEO
Leonard L. Mazur
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2017-06-09 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:1.81M
Value:$1.55M
VANGUARD GROUP INC
Shares:166.39K
Value:$142.51K
ARGENT WEALTH MANAGEMENT LLC
Shares:164.44K
Value:$140.85K
Summary
Showing Top 3 of 45